{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Metformin+XR%2C+500+mg&page=2",
    "query": {
      "intervention": "Metformin XR, 500 mg",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 50,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Metformin+XR%2C+500+mg&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Metformin+XR%2C+500+mg&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T02:47:14.270Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02851212",
      "title": "A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Metformin Extended Release (XR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 44,
      "start_date": "2016-08",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2016-12-02",
      "last_synced_at": "2026-10-06T02:47:14.270Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02851212"
    },
    {
      "nct_id": "NCT02637037",
      "title": "A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bioequivalence",
        "Fixed Dose Combination Tablets",
        "Healthy Male and Female Subjects"
      ],
      "interventions": [
        {
          "name": "dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)",
          "type": "DRUG"
        },
        {
          "name": "dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)",
          "type": "DRUG"
        },
        {
          "name": "dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)",
          "type": "DRUG"
        },
        {
          "name": "dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 80,
      "start_date": "2015-12-21",
      "completion_date": "2016-04-07",
      "has_results": true,
      "last_update_posted_date": "2018-03-13",
      "last_synced_at": "2026-10-06T02:47:14.270Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02637037"
    },
    {
      "nct_id": "NCT02846506",
      "title": "A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Metformin Extended Release (XR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 44,
      "start_date": "2016-08",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-10-06T02:47:14.270Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02846506"
    },
    {
      "nct_id": "NCT04899349",
      "title": "Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Alpelisib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Metformin XR",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin + metformin XR",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2022-04-06",
      "completion_date": "2023-05-10",
      "has_results": true,
      "last_update_posted_date": "2024-10-09",
      "last_synced_at": "2026-10-06T02:47:14.270Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04899349"
    },
    {
      "nct_id": "NCT02145559",
      "title": "A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Lung Neoplasms",
        "Cancer of Liver",
        "Lymphoma",
        "Cancer of Kidney"
      ],
      "interventions": [
        {
          "name": "Metformin XR",
          "type": "DRUG"
        },
        {
          "name": "Delayed Metformin",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2014-04",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2019-04-22",
      "last_synced_at": "2026-10-06T02:47:14.270Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02145559"
    },
    {
      "nct_id": "NCT01002807",
      "title": "Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus (T2DM)"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Metformin XR",
          "type": "DRUG"
        },
        {
          "name": "Glucophage",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 15,
      "start_date": "2009-11",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2016-10-17",
      "last_synced_at": "2026-10-06T02:47:14.270Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01002807"
    },
    {
      "nct_id": "NCT02065752",
      "title": "A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Canagliflozin, 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Metformin XR, 500 mg",
          "type": "DRUG"
        },
        {
          "name": "CANA/MET XR FDC, Formulation 1, 50 mg/500 mg",
          "type": "DRUG"
        },
        {
          "name": "CANA/MET XR FDC, Formulation 2, 50 mg/500 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 2,
      "start_date": "2014-02",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2014-06-17",
      "last_synced_at": "2026-10-06T02:47:14.270Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02065752"
    },
    {
      "nct_id": "NCT02179788",
      "title": "Metformin to Augment Low Milk Supply (MALMS) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Low Milk Supply",
        "Pre-diabetes",
        "Insulin Resistance",
        "Suppressed Lactation"
      ],
      "interventions": [
        {
          "name": "Standard care",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "20 Years and older · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2014-06",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-10-06T02:47:14.270Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02179788"
    },
    {
      "nct_id": "NCT02531308",
      "title": "Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "pegfilgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2015-07",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2022-09-28",
      "last_synced_at": "2026-10-06T02:47:14.270Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02531308"
    },
    {
      "nct_id": "NCT02087826",
      "title": "Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Genetics",
        "Metabolism",
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Mixed Meal Tolerance Test",
          "type": "OTHER"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 1017,
      "start_date": "2014-04",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-15",
      "last_synced_at": "2026-10-06T02:47:14.270Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02087826"
    }
  ]
}